Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

Posted on by

SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ — Duality Biologics (“DualityBio”) announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C9074 from DualityBio, securing global development,…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.